Furthermore, EpCAM-positive and CD90-positive HCC cells have differential sensitivity to various chemotherapeutic and targeted molecular agents, including sorafenib [14,15,16,17,18]. This evidence concerns the gene EPCAM and hepatocellular carcinoma.